3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
9
avelumab
8
Nivolumab
6
Ipilimumab
4
Radiotherapy
3
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Specimen Handling
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Interferon-beta
2
Cyclophosphamide
2
Biopsy
2
Bevacizumab
2
tremelimumab
1
sargramostim
1
sapanisertib
1
regorafenib
1
prednylidene
1
poly ICLC
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
deltacortene
1
decitabine and cedazuridine drug combination
1
bempegaldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled